ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2066

Comparative Diagnostic Efficacy of Quantitative Measurement of Echo Intensity and Texture versus Qualitative Analysis of Ultrasound Images in Myositis
Abstract Number: 2067

Clinical and Laboratory Characterization of Overlap Connective Tissue Disease in Patients with Idiopathic Inflammatory Myopathies: Results from the MYOTReCSZ Cohort
Abstract Number: 2068

Poloxamers 188 & 182 Are Effective in Repairing the Membrane Resealing Defect in Myositis
Abstract Number: 2069

Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Abstract Number: 2070

Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Abstract Number: 2071

Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
Abstract Number: 2072

Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy
Abstract Number: 2073

Ultrasound Findings of Activity in Patients with Inflammatory Myopathies and Clinical and Laboratory Comparison
Abstract Number: 2074

Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy
Abstract Number: 2075

A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)
Abstract Number: 2076

Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience
Abstract Number: 2077

Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts
Abstract Number: 2078

Increased RAGE Expression in Myositis
Abstract Number: 2079

Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Abstract Number: 2080

HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].